COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00075999" target="_blank" >RIV/65269705:_____/22:00075999 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/22:00125822
Výsledek na webu
<a href="https://ashpublications.org/blood/article/139/10/1588/477881/COVID-19-in-vaccinated-adult-patients-with" target="_blank" >https://ashpublications.org/blood/article/139/10/1588/477881/COVID-19-in-vaccinated-adult-patients-with</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood.2021014124" target="_blank" >10.1182/blood.2021014124</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Popis výsledku v původním jazyce
Coronavirus disease 2019 (COVID-19) is a life-threatening condition of high relevance for comorbid patients, such as those with baseline hematological malignancies (HM). In April 2020, the European Hematology Association - Infectious Diseases Working Party opened an open web-based registry to collect all cases of HM adult patients that developed COVID-19 infections (EPICOVIDEHA survey). This registry aimed to describe the epidemiology, risk factors, and mortality rates of HM patients. Overall, we collected 3801 valid cases, and we observed an overall mortality rate of 31%. Nearly 1 year after the first described COVID-19 case, in December 2020, the first vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were available,6,7 and administration to the highest risk populations including HM patients started.8,9 From 1 January 2021, we prospectively collected registry data on adult fully or partially vaccinated HM patients that developed COVID-19 to assess the vaccine efficacy and potentially identify categories of patients that may be less protected by vaccines. With this report, we share our findings of the first 113 patients included in the registry.
Název v anglickém jazyce
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Popis výsledku anglicky
Coronavirus disease 2019 (COVID-19) is a life-threatening condition of high relevance for comorbid patients, such as those with baseline hematological malignancies (HM). In April 2020, the European Hematology Association - Infectious Diseases Working Party opened an open web-based registry to collect all cases of HM adult patients that developed COVID-19 infections (EPICOVIDEHA survey). This registry aimed to describe the epidemiology, risk factors, and mortality rates of HM patients. Overall, we collected 3801 valid cases, and we observed an overall mortality rate of 31%. Nearly 1 year after the first described COVID-19 case, in December 2020, the first vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were available,6,7 and administration to the highest risk populations including HM patients started.8,9 From 1 January 2021, we prospectively collected registry data on adult fully or partially vaccinated HM patients that developed COVID-19 to assess the vaccine efficacy and potentially identify categories of patients that may be less protected by vaccines. With this report, we share our findings of the first 113 patients included in the registry.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Blood
ISSN
0006-4971
e-ISSN
1528-0020
Svazek periodika
139
Číslo periodika v rámci svazku
10
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
5
Strana od-do
1588-1592
Kód UT WoS článku
000769559500020
EID výsledku v databázi Scopus
2-s2.0-85126389789